89bio to Present at the Oppenheimer 31st Annual Healthcare Conference

Rhea-AI Summary

89bio, a clinical-stage biopharmaceutical company (Nasdaq: ETNB), announced its participation in the Oppenheimer 31st Annual Healthcare Conference on March 17, 2021, at 1:10 p.m. ET. The event will be virtual, and the presentation can be accessed via the Oppenheimer conference portal, with an archived version available on 89bio’s investor website. The company focuses on innovative therapies for liver and cardio-metabolic diseases, with its leading product candidate, BIO89-100, targeting nonalcoholic steatohepatitis (NASH) and severe hypertriglyceridemia (SHTG).

News Market Reaction – ETNB

+7.05%

+7.05% Session move

In the trading session that priced this news, ETNB gained 7.05%, reflecting a notable positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SAN FRANCISCO, March 11, 2021 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today announced that Company’s Management will present at the Oppenheimer 31^st Annual Healthcare Conference, a virtual event, on Wednesday, March 17, 2021 at 1:10 p.m. ET.

The presentation will be available through the Oppenheimer conference portal and an archived webcast will also be accessible in the investor section of 89bio’s website.

About 89bio

89bio is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases. The company’s lead product candidate, BIO89-100, is a specifically engineered glycoPEGylated analog of FGF21. BIO89-100 is being developed for the treatment of nonalcoholic steatohepatitis (NASH) and severe hypertriglyceridemia (SHTG). 89bio is headquartered in San Francisco with operations in Herzliya, Israel.

Investor Contact:
Ryan Martins
Chief Financial Officer
investors@89bio.com

Media Contact:
Peter Duckler
773-343-3069
pduckler@w2ogroup.com

FAQ

When will 89bio present at the Oppenheimer 31st Annual Healthcare Conference?

89bio will present on March 17, 2021, at 1:10 p.m. ET.

How can I access 89bio's presentation at the Oppenheimer conference?

The presentation will be available through the Oppenheimer conference portal and also archived on 89bio's investor website.

What is 89bio focused on developing?

89bio focuses on innovative therapies for liver and cardio-metabolic diseases.

What is BIO89-100 developed by 89bio?

BIO89-100 is a product candidate aimed at treating nonalcoholic steatohepatitis (NASH) and severe hypertriglyceridemia (SHTG).

Where is 89bio headquartered?

89bio is headquartered in San Francisco, with operations in Herzliya, Israel.